The Pharmaceutical Management Agency(PHARMAC) is considering a funding proposal that includes five treatments for multiple sclerosis (MS), namely two key MS drugs, Biogen‘sTysabri and Novartis‘ Gilenya, that are not currently funded. PHARMAC is the New ZealandCrown agency that decides, on behalf of District Health Boards, which medicines and related products are subsidized, which means that natalizumab and fingolimod may start to be prescribed by the New Zealand community and public hospitals.
Continue
~~~~~~~~~~~~~~~~~~~~
Keep CURRENT and up to date, with MS News and Information
Sign-up for emails
.
WATCH OUR MS EDUCATIONAL VIDEOS by Topic,
found here: www.youtube.com/msviewsandnews
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
